Global Adult Vaccines Market, Company Analysis and Forecast to 2021

Global Adult Vaccines Market, Company Analysis And Forecast To 2021

The adult vaccines market has been forecasted to increase at a compound annual growth rate (CAGR) of around 6% over the next five years. Adults are as likely as children to die from diseases that they can be immunized. For example, vaccination can prevent about 50% of deaths from pneumococcal disease and 80% of deaths from influenza-related complications in the elderly. Adult vaccines continue to be one of the growing segment for pharmaceutical companies. The driving factors for adult vaccines growth are an increasing acceptance of adult vaccines and the public health focus on flu prevention, as well as introductions of new vaccines. The vaccines industry also faces hindrances such as vaccine safety, shortages and delays, vaccine development time line as well as entry barriers for new manufacturers.

Adult Vaccines Market - Disease Wise Analysis

The influenza vaccines capture maximum share of the total adult vaccines market. It is the most popular and accepted vaccination amongst adults. The hepatitis vaccines account for second highest share of the total adult vaccines market in 2015. The HPV/cervical cancer vaccines and pneumococcal vaccines captures the third and fourth highest share of the adult vaccines market respectively in 2015. While vaccines for zoster shingles and DTP are also gaining ground in adult vaccines market landscape.

Adult Vaccines Market - Company Analysis

Note: Novartis divested its non-influenza vaccine business to GlaxoSmithKline (GSK) and CSL acquired Novartis influenza vaccines business.

In 2010, GSK was the leader in the adult vaccines market but it lost the leadership position to Merck. Sanofi Pasteur stands at the second position in the adult vaccines market landscape. GSK slipped to third position in the global adult vaccines market in 2014. While Pfizer stands at the fourth spot in the adult vaccines market landscape.

Adult Vaccines Market - Disease Wise Company Sales Analysis

GSK generates maximum adult vaccines sales from Hepatitis and DTP vaccines, while Sanofi Pasteur remains focused on maintaining its leadership in the influenza vaccines market. The cervical cancer and zoster shingles vaccines contributes maximum share of the total Merck adult vaccines sales. Novartis main source of adult vaccines sales revenue is the influenza vaccines.

In 2011, Sanofi Pasteur replaced GSK and became the dominant player in the influenza vaccines landscape, while in the cervical cancer vaccines market, Merck is at the forefront and is expected to maintain its dominancy over a longer period of time. GSK is the clear leader in hepatitis vaccines market.

Adult Vaccines Market - Regional Distribution

On a regional basis, the United States comprises the single largest market for adult vaccines being closely followed by Europe. Japans adult vaccines market share is expected to remain flat during the forecasting period, while Chinas adult vaccines market is likely to show continuous growth. South America and India are competing closely with each other to grab maximum share of the adult vaccines market pie.

This is the 2nd edition report on Adult Vaccines Market by iGATE RESEARCH. The report titled "Global - Adult Vaccines Market, Company Analysis and Forecast to 2021" is a 239 Page report with 141 Figures and 12 Tables. This report studies in detail the adult vaccines market disease wise, company wise sales analysis and strategic alliances, mergers and acquisitions along with growth drivers and hindrances for the vaccines market landscape.

The 9 Diseases covered in the report are analyzed from four viewpoints:

1. Adult Vaccines Market (2007 - 2021)
2. Number of Adults Vaccinated (2007 - 2021)
3. Number of Doses (2007 - 2021)
4. Company Sales Share (2010 - 2021)

The 7 Companies covered in the report are analyzed from two viewpoints:

1. Disease Wise - Adult Vaccines Sales (2007 - 2021)
2. Strategic Alliances

The 8 Regions covered in the report are analyzed from one viewpoint:

1. Adult Vaccines Market (2011 - 2021)

Global Adult Vaccines Market, Number of Adults Vaccinated and Doses - Disease Wise Analysis to 2021 (9 Disease Analysed)

1. Influenza
2. Cervical Cancer
3. Zoster Shingles
4. Pneumococcal
5. Meningococcal
6. MMRV
7. Hepatitis
8. DTP
9. Travel and Miscellaneous

Global Adult Vaccines Market - Company Analysis to 2021 (7 Companies Analysed)

1. GlaxoSmithKline
2. Sanofi Pasteur
3. Merck
4. Novartis
5. Pfizer
6. bioCSL (Seqirus)
7. Protein Sciences
8. Other Companies

Global Adult Vaccines Market - Regional Distribution to 2021 (8 Region Analysed)

1. United States
2. North America/Caribbean
3. South America
4. Europe
5. Japan
6. India
7. China
8. Rest of the World

Data Sources

iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.

1. Executive Summary

2. Global - Adult Vaccines Analysis and Forecast (2007 - 2021)

2.1 Global Adult Vaccines Market and Forecast
2.2 Global Adult Vaccines - Number of Adults Vaccinated and Forecast

3. Global Adult Vaccine Market Share Analysis and Forecast (2010 - 2021)

3.1 Global Adult Vaccines - Disease Wise Adults Vaccinated Share and Forecast
3.2 Global Adult Vaccines - Disease Wise Market Share and Forecast
3.3 Global Adult Vaccines - Company Wise Market Share and Forecast
3.4 Companies Adult Vaccines - Disease Wise Sales Share and Forecast

3.4.1 GlaxoSmithKline (GSK) - Adult Vaccines Sales Share and Forecast
3.4.2 Sanofi Pasteur - Adult Vaccines Sales Share and Forecast
3.4.3 Merck - Adult Vaccines Sales Share and Forecast
3.4.4 Novartis - Adult Vaccines Sales Share and Forecast

3.5 Adult Vaccine Disease Wise Market - Company Share and Forecast

3.5.1 Influenza Adult Vaccines - Company Market Share and Forecast
3.5.2 Cervical Cancer/HPV Adult Vaccines - Company Market Share and Forecast
3.5.3 Hepatitis Adult Vaccines - Company Market Share and Forecast
3.5.4 Pneumococcal Adult Vaccines - Company Market Share and Forecast
3.5.5 Meningococcal Adult Vaccines - Company Market Share and Forecast
3.5.6 DTP (Diphtheria, Tetanus, Pertussis) Adult Vaccines - Company Market Share and Forecast

3.6 Global Adult Vaccines Market - Region Wise Share and Forecast

4. Global Adult Vaccine Market - Disease Wise Analysis

4.1 Influenza - Adult Vaccine Analysis and Forecast (2007 - 2021)

4.1.1 Influenza - Adult Vaccine Market and Forecast
4.1.2 Influenza - Number of Adults Vaccinated and Forecast
4.1.3 Influenza - Number of Vaccines Doses and Forecast

4.2 Cervical Cancer/ HPV - Adult Vaccine Analysis and Forecast (2007 - 2021)

4.2.1 Cervical Cancer/ HPV - Adult Vaccine Market and Forecast
4.2.2 Cervical Cancer/ HPV - Number of Adults Vaccinated and Forecast
4.2.3 Cervical Cancer/ HPV - Number of Vaccines Doses and Forecast

4.3 Zoster Shingles - Adult Vaccine Analysis and Forecast (2007 - 2021)

4.3.1 Zoster Shingles - Adult Vaccine Market and Forecast
4.3.2 Zoster Shingles - Number of Adults Vaccinated and Forecast
4.3.3 Zoster Shingles - Number of Vaccines Doses and Forecast

4.4 Pneumococcal - Adult Vaccine Analysis and Forecast (2010 - 2021)

4.4.1 Pneumococcal - Adult Vaccine Market and Forecast
4.4.2 Pneumococcal - Number of Adults Vaccinated and Forecast
4.4.3 Pneumococcal - Number of Vaccines Doses and Forecast

4.5 Meningococcal - Adult Vaccine Analysis and Forecast (2010 - 2021)

4.5.1 Meningococcal - Adult Vaccine Market and Forecast
4.5.2 Meningococcal - Number of Adults Vaccinated and Forecast
4.5.3 Meningococcal - Number of Vaccines Doses and Forecast

4.6 Measles, Mumps, Rubella and Varicella (MMRV) - Adult Vaccine Analysis and Forecast (2010 - 2021)

4.6.1 Measles, Mumps, Rubella and Varicella (MMRV) - Adult Vaccine Market and Forecast
4.6.2 Measles, Mumps, Rubella and Varicella (MMRV) - Number of Adults Vaccinated and Forecast
4.6.3 Measles, Mumps, Rubella and Varicella (MMRV) - Number of Vaccines Doses and Forecast

4.7 Hepatitis - Adult Vaccine Analysis and Forecast (2007 - 2021)

4.7.1 Hepatitis - Adult Vaccine Market and Forecast
4.7.2 Hepatitis - Number of Adults Vaccinated and Forecast
4.7.3 Hepatitis - Number of Vaccines Doses and Forecast

4.8 Diphtheria, Tetanus, Pertussis (DTP) - Adult Vaccine Analysis and Forecast (2007 - 2021)

4.8.1 Diphtheria, Tetanus, Pertussis (DTP) - Adult Vaccine Market and Forecast
4.8.2 Diphtheria, Tetanus, Pertussis (DTP) - Number of Adults Vaccinated and Forecast
4.8.3 Diphtheria, Tetanus, Pertussis (DTP) - Number of Vaccines Doses and Forecast

4.9 Travel and Miscellaneous - Adult Vaccine Analysis and Forecast (2007 - 2021)

5. Global Adult Vaccine Market - Company Analysis and Strategic Alliances

5.1 GlaxoSmithKline

5.1.1 GlaxoSmithKline (GSK) - Adult Vaccine Sales and Forecast
5.1.2 Strategic Alliances of GlaxoSmithKline (GSK)

5.2 Sanofi Pasteur

5.2.1 Sanofi Pasteur Vaccines Sales and Forecast
5.2.2 Strategic Alliances of Sanofi Pasteur

5.3 Merck

5.3.1 Merck Vaccines Sales and Forecast
5.3.2 Strategic Alliances of Merck

5.4 Novartis

5.4.1 Novartis Vaccines Sales
5.4.2 Strategic Alliances of Novartis

5.5 Pfizer

5.5.1 Pfizer Adult Vaccines Sales and Forecast
5.5.2 Strategic Alliances of Pfizer

5.6 bioCSL (Now Seqirus)

5.6.1 bioCSL Adult Vaccines Sales and Forecast
5.6.2 Strategic Alliances of bioCSL

5.7 Protein Sciences

5.7.1 Protein Sciences Adult Vaccines Sales and Forecast

5.8 Other Companies Sales and Forecast

6. Global Adult Vaccine - Disease Wise Company Sales and Forecast (2007 - 2021)

6.1 GlaxoSmithKline (GSK) - Adult Vaccines Sales and Forecast

6.1.1 GlaxoSmithKline (GSK) - Influenza Adult Vaccines Sales and Forecast
6.1.2 GlaxoSmithKline (GSK) - Cervical Cancer/HPV Adult Vaccines Sales and Forecast
6.1.3 GlaxoSmithKline (GSK) - Hepatitis Adult Vaccines Sales and Forecast
6.1.4 GlaxoSmithKline (GSK) - DTP Adult Vaccines Sales and Forecast
6.1.5 GlaxoSmithKline (GSK) - Meningococcal Adult Vaccines Sales and Forecast

6.2 Sanofi Pasteur - Adult Vaccines Sales and Forecast

6.2.1 Sanofi Pasteur - Influenza Adult Vaccines Sales and Forecast
6.2.2 Sanofi Pasteur - DTP Adult Vaccines Sales and Forecast
6.2.3 Sanofi Pasteur - Meningococcal Adult Vaccines Sales and Forecast

6.3 Merck - Adult Vaccines Sales and Forecast

6.3.1 Merck - Cervical Cancer/HPV Adult Vaccines Sales and Forecast
6.3.2 Merck - Zoster Shingles Adult Vaccines Sales and Forecast
6.3.3 Merck - Pneumococcal Adult Vaccines Sales and Forecast
6.3.4 Merck - MMRV Adult Vaccines Sales and Forecast
6.3.5 Merck - Hepatitis Adult Vaccines Sales and Forecast

6.4 Novartis - Adult Vaccines Sales and Forecast

6.4.1 Novartis - Influenza Adult Vaccines Sales and Forecast
6.4.2 Novartis - Meningococcal Adult Vaccines Sales and Forecast

6.5 Pfizer - Adult Vaccines Sales and Forecast

6.5.1 Pfizer - Pneumococcal Adult Vaccines Sales and Forecast

6.6 bioCSL - Adult Vaccines Sales and Forecast

6.6.1 bioCSL - Influenza Adult Vaccines Sales and Forecast

6.7 Protein Sciences - Adult Vaccines Sales and Forecast

6.7.1 Protein Sciences - Influenza Adult Vaccines Sales and Forecast

7. Global Adult Vaccine Market - Regional Distribution (2011 - 2021)

7.1 United States - Adult Vaccine Market and Forecast
7.2 North America/Caribbean - Adult Vaccine Market and Forecast
7.3 South America - Adult Vaccine Market and Forecast
7.4 Europe - Adult Vaccine Market and Forecast
7.5 Japan - Adult Vaccine Market and Forecast
7.6 India - Adult Vaccine Market and Forecast
7.7 China - Adult Vaccine Market and Forecast
7.8 Rest of the World (ROW) - Adult Vaccine Market and Forecast

8. Major Vaccine Related Acquisitions (2005-2015)

9. Adult Vaccines Market - Driving Factors

9.1 GAVI Model Fuelling Vaccine Manufacturers

9.1.1 The Partnership Model
9.1.2 The Business Model

9.2 Global Immunization Vision and Strategy (GIVS)
9.3 Growing Vaccine Availability in United States
9.4 The Vaccine Injury Compensation Program
9.5 The Vaccine Safety Data link Project
9.6 Transformation of Vaccine Technologies
9.7 Global Vaccine Action Plan by WHO (2011 - 2020)
9.8 Continuous Focus on Effective Communication Strategies

10. Adult Vaccines Market - Challenges

10.1 Hurdles to Optimal use of Licensed Vaccines

10.1.1 Technical Obstacles
10.1.2 Economic obstacles
10.1.3 Cultural Obstacles

10.2 Shortening the Timeline for Vaccine Development
10.3 Complexity of Vaccine Development and Approval System Thwarts Product Development

10.3.1 Legal Obstacles
10.3.2 General Technical Barriers
10.3.3 Economic Barriers
10.3.4 Regulatory Barriers

10.4 Refusal/Resistance to Vaccination
10.5 Vaccine Adverse Event Reporting System
10.6 Vaccine Shortages and Delays
10.7 Obstacles in Vaccine Research and Development
10.8 Barriers to New Entrants in the Vaccines Market

List of Figures:

Figure 2-1: Global - Adult Vaccines Market (Million US$), 2007 - 2015
Figure 2-2: Global - Forecast for Adult Vaccines Market (Million US$), 2016 - 2021
Figure 2-3: Global - Number of Adults Vaccinated (Million), 2007 - 2015
Figure 2-4: Global - Forecast for Number of Adults Vaccinated (Million), 2016 - 2021

Figure 3-1: GlaxoSmithKline (GSK) - Adult Vaccines Sales Share (Percent), 2009 - 2015
Figure 3-2: GlaxoSmithKline (GSK) - Forecast for Adult Vaccines Sales Share (Percent), 2016 - 2021
Figure 3-3: Sanofi Pasteur - Adult Vaccines Sales Share (Percent), 2010 - 2015
Figure 3-4: Sanofi Pasteur - Forecast for Adult Vaccines Sales Share (Percent), 2016 - 2021
Figure 3-5: Merck - Adult Vaccines Sales Share (Percent), 2010 - 2015
Figure 3-6: Merck - Forecast for Adult Vaccines Sales Share (Percent), 2016 - 2021
Figure 3-7: Novartis - Adult Vaccines Sales Share (Percent), 2010 - 2014
Figure 3-8: Cervical Cancer/HPV Adult Vaccines - Company Market Share (Percent), 2007 - 2015
Figure 3-9: Cervical Cancer/HPV Adult Vaccines - Forecast for Company Market Share (Percent), 2016 - 2021
Figure 3-10: Hepatitis Adult Vaccines - Company Market Share (Percent), 2008 - 2015
Figure 3-11: Hepatitis Adult Vaccines - Forecast for Company Market Share (Percent), 2016 - 2021
Figure 3-12: Pneumococcal Adult Vaccines - Company Market Share (Percent), 2010 - 2015
Figure 3-13: Pneumococcal Adult Vaccines - Forecast for Company Market Share (Percent), 2016 - 2021
Figure 3-14: Meningococcal Adult Vaccines - Company Market Share (Percent), 2010 - 2014
Figure 3-15: Pneumococcal Adult Vaccines - Company Market Share and Forecast (Percent), 2015 - 2021
Figure 3-16: DTP Adult Vaccines - Company Market Share (Percent), 2010 - 2014
Figure 3-17: DTP Adult Vaccines - Forecast for Company Market Share (Percent), 2016 - 2021
Figure 3-18: Region Wise - Adult Vaccines Market Share (Percent), 2011 - 2015
Figure 3-19: Region Wise - Forecast for Adult Vaccines Market Share (Percent), 2016 - 2021

Figure 4-1: Influenza - Adult Vaccine Market (Million US$), 2007 - 2015
Figure 4-2: Influenza - Forecast for Adult Vaccine Market (Million US$), 2016 - 2021
Figure 4-3: Influenza - Number of Adults Vaccinated (Million), 2007 - 2015
Figure 4-4: Influenza - Forecast for Number of Adults Vaccinated (Million), 2016 - 2021
Figure 4-5: Influenza - Number of Vaccines Doses (Million), 2007 - 2015
Figure 4-6: Influenza - Forecast for Number of Vaccines Doses (Million), 2016 - 2021
Figure 4-7: Cervical Cancer/ HPV - Adult Vaccine Market (Million US$), 2007 - 2015
Figure 4-8: Cervical Cancer/ HPV - Forecast for Adult Vaccine Market (Million US$), 2016 - 2021
Figure 4-9: Cervical Cancer/ HPV - Number of Adults Vaccinated (Million), 2007 - 2015
Figure 4-10: Cervical Cancer/ HPV - Forecast for Number of Adults Vaccinated (Million), 2016 - 2021
Figure 4-11: Cervical Cancer/ HPV - Number of Vaccines Doses (Million), 2007 - 2015
Figure 4-12: Cervical Cancer/ HPV - Forecast for Number of Vaccines Doses (Million), 2016 - 2021
Figure 4-13: Zoster Shingles - Adult Vaccine Market (Million US$), 2007 - 2015
Figure 4-14: Zoster Shingles - Forecast for Adult Vaccine Market (Million US$), 2016 - 2021
Figure 4-15: Zoster Shingles - Number of Adults Vaccinated (Million), 2007 - 2015
Figure 4-16: Zoster Shingles - Forecast for Number of Adults Vaccinated (Million), 2016 - 2021
Figure 4-17: Zoster Shingles - Number of Vaccines Doses (Million), 2007 - 2015
Figure 4-18: Zoster Shingles - Forecast for Number of Vaccines Doses (Million), 2016 - 2021
Figure 4-19: Pneumococcal - Adult Vaccine Market (Million US$), 2010 - 2015
Figure 4-20: Pneumococcal - Forecast for Adult Vaccine Market (Million US$), 2016 - 2021
Figure 4-21: Pneumococcal - Number of Adults Vaccinated (Million), 2010 - 2015
Figure 4-22: Pneumococcal - Forecast for Number of Adults Vaccinated (Million), 2016 - 2021
Figure 4-23: Pneumococcal - Number of Vaccines Doses (Million), 2010 - 2015
Figure 4-24: Pneumococcal - Forecast for Number of Vaccines Doses (Million), 2016 - 2021
Figure 4-25: Meningococcal - Adult Vaccine Market (Million US$), 2010 - 2015
Figure 4-26: Meningococcal - Forecast for Adult Vaccine Market (Million US$), 2016 - 2021
Figure 4-27: Meningococcal - Number of Adults Vaccinated (Million), 2010 - 2015
Figure 4-28: Meningococcal - Forecast for Number of Adults Vaccinated (Million), 2016 - 2021
Figure 4-29: Meningococcal - Number of Vaccines Doses (Million), 2010 - 2015
Figure 4-30: Meningococcal - Forecast for Number of Vaccines Doses (Million), 2016 - 2021
Figure 4-31: MMRV - Adult Vaccine Market (Million US$), 2007 - 2015
Figure 4-32: MMRV - Forecast for Adult Vaccine Market (Million US$), 2016 - 2021
Figure 4-33: MMRV - Number of Adults Vaccinated (Million), 2007 - 2015
Figure 4-34: MMRV - Forecast for Number of Adults Vaccinated (Million), 2016 - 2021
Figure 4-35: MMRV - Number of Vaccines Doses (Million), 2007 - 2015
Figure 4-36: MMRV - Forecast for Number of Vaccines Doses (Million), 2016 - 2021
Figure 4-37: Hepatitis - Adult Vaccine Market (Million US$), 2007 - 2015
Figure 4-38: Hepatitis - Forecast for Adult Vaccine Market (Million US$), 2016 - 2021
Figure 4-39: Hepatitis - Number of Adults Vaccinated (Million), 2007 - 2015
Figure 4-40: Hepatitis - Forecast for Number of Adults Vaccinated (Million), 2016 - 2021
Figure 4-41: Hepatitis - Number of Vaccines Doses (Million), 2007 - 2015
Figure 4-42: Hepatitis - Forecast for Number of Vaccines Doses (Million), 2016 - 2021
Figure 4-43: DTP - Adult Vaccine Market (Million US$), 2010 - 2015
Figure 4-44: DTP - Forecast for Adult Vaccine Market (Million US$), 2016 - 2021
Figure 4-45: DTP - Number of Adults Vaccinated (Million), 2010 - 2015
Figure 4-46: DTP - Forecast for Number of Adults Vaccinated (Million), 2016 - 2021
Figure 4-47: DTP - Number of Vaccines Doses (Million), 2010 - 2015
Figure 4-48: DTP - Forecast for Number of Vaccines Doses (Million), 2016 - 2021
Figure 4-49: Travel and Miscellaneous - Adult Vaccine Market (Million US$), 2007 - 2015
Figure 4-50: Travel and Miscellaneous - Forecast for Adult Vaccine Market (Million US$), 2016 - 2021

Figure 5-1: GlaxoSmithKline (GSK) - Adult Vaccine Sales (Million US$), 2007 - 2015
Figure 5-2: GlaxoSmithKline (GSK) - Forecast for Adult Vaccine Sales (Million US$), 2016 - 2021
Figure 5-3: Sanofi Pasteur - Adult Vaccine Sales (Million US$), 2010 - 2015
Figure 5-4: Sanofi Pasteur - Forecast for Adult Vaccine Sales (Million US$), 2016 - 2021
Figure 5-5: Sanofi Pasteur - Pipeline Vaccines candidates (Phase III), April 2016
Figure 5-8: Merck - Adult Vaccine Sales (Million US$), 2007 - 2015
Figure 5-9: Merck - Forecast for Adult Vaccine Sales (Million US$), 2016 - 2021
Figure 5-10: Novartis - Adult Vaccine Sales (Million US$), 2010 - 2015
Figure 5-11: Pfizer - Adult Vaccine Sales (Million US$), 2010 - 2015
Figure 5-12: Pfizer - Forecast for Adult Vaccine Sales (Million US$), 2015 - 2020
Figure 5-13: bioCSL - Adult Vaccine Sales (Million US$), 2010 - 2015
Figure 5-14: bioCSL - Forecast for Adult Vaccine Sales (Million US$), 2016 - 2021
Figure 5-15: Protein Sciences - Adult Vaccine Sales (Million US$), 2013 - 2015
Figure 5-16: Protein Sciences - Forecast for Adult Vaccine Sales (Million US$), 2016 - 2021
Figure 5-17: Other Companies - Adult Vaccine Sales (Million US$), 2010 - 2015
Figure 5-18: Other Companies - Forecast for Adult Vaccine Sales (Million US$), 2015 - 2020

Figure 6-1: GlaxoSmithKline (GSK) - Influenza Adult Vaccines Sales (Million US$), 2007 - 2015
Figure 6-2: GlaxoSmithKline (GSK) - Forecast for Influenza Adult Vaccines Sales (Million US$), 2016 - 2021
Figure 6-3: GlaxoSmithKline (GSK) - Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2007 - 2015
Figure 6-4: GlaxoSmithKline (GSK) - Forecast for Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2016 - 2021
Figure 6-5: GlaxoSmithKline (GSK) - Hepatitis Adult Vaccines Sales (Million US$), 2007 - 2015
Figure 6-6: GlaxoSmithKline (GSK) - Forecast for Hepatitis Adult Vaccines Sales (Million US$), 2016 - 2021
Figure 6-7: GlaxoSmithKline (GSK) - DTP Adult Vaccines Sales (Million US$), 2007 - 2015
Figure 6-8: GlaxoSmithKline (GSK) - Forecast for DTP Adult Vaccines Sales (Million US$), 2016 - 2021
Figure 6-9: GlaxoSmithKline (GSK) - Meningococcal Adult Vaccines Sales and Forecast (Million US$), 2015 - 2021
Figure 6-10: Sanofi Pasteur - Influenza Adult Vaccines Sales (Million US$), 2009 - 2015
Figure 6-11: Sanofi Pasteur - Forecast for Influenza Adult Vaccines Sales (Million US$), 2016 - 2021
Figure 6-12: Sanofi Pasteur - DTP Adult Vaccines Sales (Million US$), 2010 - 2015
Figure 6-13: Sanofi Pasteur - Forecast for DTP Adult Vaccines Sales (Million US$), 2016 - 2021
Figure 6-14: Sanofi Pasteur - Meningococcal Adult Vaccines Sales (Million US$), 2009 - 2015
Figure 6-15: Sanofi Pasteur - Forecast for Meningococcal Adult Vaccines Sales (Million US$), 2016 - 2021
Figure 6-16: Merck - Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2007 - 2015
Figure 6-17: Merck - Forecast for Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2016 - 2021
Figure 6-18: Merck - Zoster Shingles Adult Vaccines Sales (Million US$), 2007 - 2015
Figure 6-19: Merck - Forecast for Zoster Shingles Adult Vaccines Sales (Million US$), 2016 - 2021
Figure 6-20: Merck - Pneumococcal Adult Vaccines Sales (Million US$), 2007 - 2015
Figure 6-21: Merck - Forecast for Pneumococcal Adult Vaccines Sales (Million US$), 2016 - 2021
Figure 6-22: Merck - MMRV Adult Vaccines Sales (Million US$), 2007 - 2015
Figure 6-23: Merck - Forecast for MMRV Adult Vaccines Sales (Million US$), 2016 - 2021
Figure 6-24: Merck - Hepatitis Adult Vaccines Sales (Million US$), 2007 - 2015
Figure 6-25: Merck - Forecast for Hepatitis Adult Vaccines Sales (Million US$), 2016 - 2021
Figure 6-26: Novartis - Influenza Adult Vaccines Sales (Million US$), 2010 - 2015
Figure 6-27: Novartis - Meningococcal Adult Vaccines Sales (Million US$), 2010 - 2014
Figure 6-28: Pfizer - Pneumococcal Adult Vaccines Sales (Million US$), 2010 - 2015
Figure 6-29: Novartis - Forecast for Pneumococcal Adult Vaccines Sales (Million US$), 2016 - 2021
Figure 6-30: bioCSL - Influenza Adult Vaccines Sales (Million US$), 2010 - 2015
Figure 6-31: bioCSL - Forecast for Influenza Adult Vaccines Sales (Million US$), 2016 - 2021
Figure 6-32: Protein Sciences - Influenza Adult Vaccines Sales (Million US$), 2013 - 2015
Figure 6-33: Protein Sciences - Forecast for Influenza Adult Vaccines Sales (Million US$), 2016 - 2021

Figure 7-1: United States - Adult Vaccines Market (Million US$), 2011 - 2015
Figure 7-2: United States - Forecast for Adult Vaccines Market (Million US$), 2016 - 2021
Figure 7-3: North America/Caribbean - Adult Vaccines Market (Million US$), 2011 - 2015
Figure 7-4: North America/Caribbean - Forecast for Adult Vaccines Market (Million US$), 2016 - 2021
Figure 7-5: South America - Adult Vaccines Market (Million US$), 2011 - 2015
Figure 7-6: South America - Forecast for Adult Vaccines Market (Million US$), 2016 - 2021
Figure 7-7: Europe - Adult Vaccines Market (Million US$), 2011 - 2015
Figure 7-8: Europe - Forecast for Adult Vaccines Market (Million US$), 2016 - 2021
Figure 7-9: Japan - Adult Vaccines Market (Million US$), 2011 - 2015
Figure 7-10: Japan - Forecast for Adult Vaccines Market (Million US$), 2016 - 2021
Figure 7-11: India - Adult Vaccines Market (Million US$), 2011 - 2015
Figure 7-12: India - Forecast for Adult Vaccines Market (Million US$), 2016 - 2021
Figure 7-13: China - Adult Vaccines Market (Million US$), 2011 - 2015
Figure 7-14: China - Forecast for Adult Vaccines Market (Million US$), 2016 - 2021
Figure 7-15: ROW - Adult Vaccines Market (Million US$), 2011 - 2015
Figure 7-16: ROW - Forecast for Adult Vaccines Market (Million US$), 2016 - 2021

Figure 9-1: US - Number of Retail Clinics offering Vaccination (Number), 2007 - 2012

List of Tables:

Table 3-1: Global - Disease Wise Adults Vaccinated Share (Percent), 2010 - 2015
Table 3-2: Global - Forecast for Disease Wise Adults Vaccinated Share (Percent), 2016 - 2021
Table 3-3: Global Adult Vaccines - Disease Wise Market Share (Percent), 2010 - 2015
Table 3-4: Global Adult Vaccines - Forecast for Disease Wise Market Share (Percent), 2016 - 2021
Table 3-5: Global Adult Vaccines - Company Wise Market Share (Percent), 2010 - 2015
Table 3-6: Global Adult Vaccines - Forecast for Company Wise Market Share (Percent), 2016 - 2021
Table 3-7: Influenza Adult Vaccines - Company Market Share (Percent), 2010 - 2015
Table 3-8: Influenza Adult Vaccines - Forecast for Company Market Share (Percent), 2016 - 2021

Table 8-1: Worldwide - Major Vaccine Related Acquisitions, (2005 - 2015)

Table 9-1: Global - Total Future Deaths Averted through Vaccination (Million), 2011 - 2020
Table 9-2: Global Goal-Level Indicators, 2015 & 2020
Table 9-3: Improvement Strategies or Requirements - the Joint Commission and the Projects Collaborating Organizations

Global Adult Vaccines Market, Company Analysis And Forecast To 2021

PRICING

Categories